<DOC>
	<DOCNO>NCT00002064</DOCNO>
	<brief_summary>To compare pyrimethamine intravenous ( IV ) clindamycin vs. pyrimethamine sulfonamide treatment AIDS patient central nervous system ( CNS ) Toxoplasma gondii .</brief_summary>
	<brief_title>Toxoplasmic Encephalitis Patients With AIDS . Treatment Prevention Relapse</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Toxoplasmosis</mesh_term>
	<mesh_term>Toxoplasmosis , Cerebral</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>Exclusion Criteria Coexisting Condition : Patients follow condition exclude : Opportunistic infection ( Pneumocystis carinii pneumonia ( PCP ) , cryptococcal meningitis ) condition ( brain abscess ) would make treatment result difficult interpret due concurrent infection , disease , therapy . Patients opportunistic infection brain disease exclude . Patients AIDS cerebral toxoplasmosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1989</verification_date>
	<keyword>Sulfonamides</keyword>
	<keyword>Toxoplasmosis</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pyrimethamine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Encephalitis</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Clindamycin</keyword>
</DOC>